Neurology

Your Article Summary

See Latest Articles

Primary central nervous system lymphoma: The role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy
Cancer, 07/24/08

Ekenel M et al. - Consolidation treatment with whole-brain radiation therapy (WBRT), high-dose cytarabine (HDAC), or both does not appear to improve survival in patients who achieved a complete response (CR) with induction MTX-based therapy. Age, Karnofsky performance scale (KPS), and risk of delayed neurotoxicity must be considered in the choice of consolidation regimens.

• A retrospective study to assess the impact of consolidation treatment after a CR to initial induction chemotherapy on disease control and survival
• 122 pts who achieved a CR after initial MTX-based chemotherapy were analyzed
• The benefit of consolidation WBRT, HDAC or both on failure-free (FFS) and overall survival (OS) was assessed

• Median f/u of 60 mos; FFS was longer in pts who received WBRT plus HDAC as consolidation treatment
• No difference in OS among pts who received no consolidation treatment, HDAC alone, WBRT plus HDAC, or WBRT alone
• Age and KPS were the only independent prognostic factors
• Pts who received WBRT alone or in combination with HDAC had higher rates of neurotoxicity

Today in Neurologic Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

A heritable predisposition to pituitary tumors
Pituitary, 12/18/09

Temozolomide (Temodar) and capecitabine (Xeloda) treatment of an aggressive corticotroph pituitary tumor
Pituitary, 12/18/09

Complete percutaneous treatment of vertebral body tumors causing spinal canal compromise using a transpedicular cavitation, cement augmentation, and radiosurgical technique
Neurosurgical Focus, 12/18/09

 See all of Neurologic Oncology